ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

IMPACT OF LOSARTAN AND GLIBENCLAMIDE GIVEN IN COMBINATION ON THE METABOLISM IN PATIENTS WITH HYPERTENSION AND NIDDM

Dr Rana Sajid Ali, Dr Qudsia Mujeeb, Dr Rao Salman Aziz

Aim: To observe the effect of treatment with losartan given in combination with glibenclamide on metabolism (fat and carbohydrates) and physiological factors (BMI, weight and blood pressure) in patients with hypertension with NIDDM. Study Design: An Observational Study. Place and Duration: In Pharmacology and Therapeutics Department in collaboration with medicine department of Mayo Hospital Lahore for three months duration from June 2018 to August 2018. Methods: The collective drug therapy with tablet glibenclamide 5 mg and tablet losartan 50 mg (attuned rendering to the individual glycemic control) was given to 30 newly identified uncomplicated NIDDM patients with hypertension of both genders between thirty to fifty five years of age for a period of two months. Blood pressure and Fasting glucose were recorded one time in a week, lipid profile (VLDL, total cholesterol, triglycerides, LDL and HDL cholesterol), fasting insulin and BMI calculated during the analysis i.e. Zero and at 60 day two times. Results and conclusion: Substantial reduction in fasting blood sugar (P <0.001) was observed and fasting insulin (p <0.05) was rise significantly. There were no substantial variations (P = NS) in triglycerides, VLDL, LDL cholesterol and total serum. A major rise in HDL cholesterol (P less than 0.05) was noted. Noteworthy decrease in both diastolic and systolic blood pressure (less than 0.001 P value) was observed. A negligible effect on BMI and weight. Combination treatment with glibenclamide and losartan had a major effect on fat metabolism (HDL cholesterol only), blood pressure and carbohydrate metabolism in patients of hypertension with NIDDM. Key Words: Losartan, glibenclamide, physiological factors, metabolism.

FULL TEXT